Chinese Trio Lights Up NASDAQ in January 2025
The new year kicked off with three Chinese companies making waves on Wall Street as INLIF LIMITED, Jilin Zhengye Biological Products, and Ascentage Pharma Group successfully debuted on NASDAQ within weeks of each other, offering global investors fresh opportunities in emerging markets.

INLIF LIMITED (Ticker: INLF)
The robotics equipment manufacturer, ultimately controlled by Fujian''s Iwart Robotics, went public on January 2, 2025. Having secretly filed with the SEC back in November 2023, the company finally unveiled its prospectus on May 21, 2024 after 18 months of preparations. The IPO priced at $4����ℎ���,������2��������ℎ�����������$8 million.

Zhengye Biological (Ticker: ZYBT)
This veterinary biotech veteran with 50+ years of history - originally established as the Harbin Veterinary Biopharmaceutical Factory under China''s Ministry of Agriculture - showcased strong performance on its January 7 debut. Opening at $3.77,�ℎ������������$6.10 intraday before settling at $4.86�����,�����������21.50$229 million.

Ascentage Pharma (Ticker: ASPH)
Completing the trifecta on January 24 was this dual-listed biopharma player, already traded on Hong Kong''s main board since 2019. The global drug developer priced its NASDAQ ADS at $17.25���ℎ,��������$126 million in fresh capital to fuel R&D pipelines. This cross-border listing cements Ascentage''s position as China''s innovative pharma bridge between Asian and U.S. markets.

All three listings demonstrate growing international appetite for China''s specialized manufacturers, agribiotech leaders, and healthcare innovators - despite ongoing market volatility.

As highlighted in AGBA''s year-end review, 2024 marked a decade-high surge in U.S. listings by Chinese companies, though with striking market polarization. SPAC-listed firms notably outperformed, achieving higher average market valuations compared to traditional IPO counterparts.

With financing demands escalating and exchanges potentially raising listing thresholds, companies must act decisively: Strategic preparation, operational upgrades, and pathway selection (SPAC vs. conventional IPO) now determine success in this efficiency-driven race.

Looking ahead to 2025, AGBA anticipates more Chinese enterprises to conquer Wall Street, showcasing China''s corporate innovation while expanding global investors'' access to high-growth opportunities.

Analysis compiled by AGBA through review of SEC filings, market data, and industry intelligence.